Clinical studies have also demonstrated that programmed cell death-1 (PD-1) inhibitors, such as pembrolizumab, are effective in B-cell lymphoma [17], but their value in primary lymphoma of the prostate remains to be further investigated. The gene discussed is PDCD1; the disease is B-cell non-Hodgkin lymphoma.